These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 3011242

  • 1. Conditioned tumorigenicity of activated oncogenes.
    Klein G, Klein E.
    Cancer Res; 1986 Jul; 46(7):3211-24. PubMed ID: 3011242
    [Abstract] [Full Text] [Related]

  • 2. Chromosomal translocations in B-cell derived tumors.
    Klein G.
    Princess Takamatsu Symp; 1986 Jul; 17():159-70. PubMed ID: 3332008
    [Abstract] [Full Text] [Related]

  • 3. Constitutive activation of oncogenes by chromosomal translocations in B-cell derived tumors.
    Klein G.
    AIDS Res; 1986 Dec; 2 Suppl 1():S167-76. PubMed ID: 3030345
    [Abstract] [Full Text] [Related]

  • 4. EBV-B cell interactions: immortalization, rescue from apoptosis, tumorigenicity (a short review).
    Klein G.
    Acta Microbiol Immunol Hung; 1996 Dec; 43(2-3):97-105. PubMed ID: 8876725
    [Abstract] [Full Text] [Related]

  • 5. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
    Arasi VE, Lieberman R, Sandlund J, Kiwanuka J, Novikovs L, Kirsch I, Hollis G, Magrath IT.
    Cancer Res; 1989 Jun 15; 49(12):3235-41. PubMed ID: 2497974
    [Abstract] [Full Text] [Related]

  • 6. Forward and reverse changes in Ig/myc translocation carrying tumors.
    Klein G.
    Princess Takamatsu Symp; 1989 Jun 15; 20():135-42. PubMed ID: 2562178
    [Abstract] [Full Text] [Related]

  • 7. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
    Sandlund JT, Neckers LM, Schneller HE, Woodruff LS, Magrath IT.
    Cancer Res; 1993 Jan 01; 53(1):127-32. PubMed ID: 8416737
    [Abstract] [Full Text] [Related]

  • 8. The involvement of oncogenes and suppressor genes in human neoplasia.
    Brodeur GM.
    Adv Pediatr; 1987 Jan 01; 34():1-44. PubMed ID: 3318293
    [Abstract] [Full Text] [Related]

  • 9. c-MYC impairs immunogenicity of human B cells.
    Schlee M, Schuhmacher M, Hölzel M, Laux G, Bornkamm GW.
    Adv Cancer Res; 2007 Jan 01; 97():167-88. PubMed ID: 17419945
    [Abstract] [Full Text] [Related]

  • 10. The human breast carcinoma cell line SW 613-S: an experimental system to study tumor heterogeneity in relation to c-myc amplification, growth factor production and other markers (review).
    Lavialle C, Modjtahedi N, Lamonerie T, Frebourg T, Landin RM, Fossar N, Lhomond G, Cassingena R, Brison O.
    Anticancer Res; 1989 Jan 01; 9(5):1265-79. PubMed ID: 2686529
    [Abstract] [Full Text] [Related]

  • 11. The transgenic window on lymphoid malignancy.
    Adams JM, Harris AW, Vaux DL, Alexander WS, Rosenbaum H, Klinken SP, Strasser A, Bath ML, McNeall J, Cory S.
    Princess Takamatsu Symp; 1989 Jan 01; 20():297-309. PubMed ID: 2518688
    [Abstract] [Full Text] [Related]

  • 12. Immunological aspects of B-cell derived tumors in humans and rodents.
    Klein G.
    Princess Takamatsu Symp; 1988 Jan 01; 19():3-13. PubMed ID: 2855874
    [Abstract] [Full Text] [Related]

  • 13. Translocations among antibody genes in human cancer.
    Leder P.
    IARC Sci Publ; 1985 Jan 01; (60):341-57. PubMed ID: 4065947
    [Abstract] [Full Text] [Related]

  • 14. Mechanism of carcinogenesis: the role of oncogenes, transcriptional enhancers and growth factors.
    Spandidos DA.
    Anticancer Res; 1985 Jan 01; 5(5):485-98. PubMed ID: 3904595
    [Abstract] [Full Text] [Related]

  • 15. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation.
    Leucci E, Cocco M, Onnis A, De Falco G, van Cleef P, Bellan C, van Rijk A, Nyagol J, Byakika B, Lazzi S, Tosi P, van Krieken H, Leoncini L.
    J Pathol; 2008 Dec 01; 216(4):440-50. PubMed ID: 18802929
    [Abstract] [Full Text] [Related]

  • 16. Rearrangement of the c-myc oncogene with heavy-chain immunoglobulin enhancer in tumor DNA from an acute lymphoblastic leukemia patient.
    Guerrasio A, Avanzi GC, Pegoraro L, Estivill X, Serra A, Giubellino MC, Fierro MT, Novarino A, Foa R, Saglio G.
    J Natl Cancer Inst; 1987 May 01; 78(5):845-51. PubMed ID: 3106693
    [Abstract] [Full Text] [Related]

  • 17. Cellular oncogenes and lymphocyte activation.
    Schneider-Schaulies J, Knauer R, Schimpl A, Wecker E.
    Behring Inst Mitt; 1987 Jun 01; (81):110-9. PubMed ID: 3115245
    [Abstract] [Full Text] [Related]

  • 18. Molecular genetics of B- and T-cell neoplasia.
    Haluska FG, Tsujimoto Y, Croce CM.
    Princess Takamatsu Symp; 1986 Jun 01; 17():151-8. PubMed ID: 3332007
    [Abstract] [Full Text] [Related]

  • 19. Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss.
    Jox A, Taquia E, Vockerodt M, Draube A, Pawlita M, Möller P, Bullerdiek J, Diehl V, Wolf J.
    Cancer Res; 1998 Nov 01; 58(21):4930-9. PubMed ID: 9810002
    [Abstract] [Full Text] [Related]

  • 20. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
    Bemark M, Neuberger MS.
    Oncogene; 2000 Jul 13; 19(30):3404-10. PubMed ID: 10918597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.